Alimera Sciences (ALIM) Getting Somewhat Favorable News Coverage, Report Shows

Media stories about Alimera Sciences (NASDAQ:ALIM) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alimera Sciences earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.8132554679008 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of ALIM traded up $0.02 during mid-day trading on Friday, hitting $1.10. 234,211 shares of the company were exchanged, compared to its average volume of 104,140. Alimera Sciences has a 1-year low of $1.01 and a 1-year high of $1.70. The company has a quick ratio of 3.91, a current ratio of 4.07 and a debt-to-equity ratio of -0.64. The company has a market cap of $75.58, a PE ratio of -3.79 and a beta of 1.72.

How to Become a New Pot Stock Millionaire

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.07). The company had revenue of $9.14 million for the quarter, compared to analysts’ expectations of $9.60 million. sell-side analysts expect that Alimera Sciences will post -0.06 earnings per share for the current year.

Several research firms have recently issued reports on ALIM. Zacks Investment Research lowered shares of Alimera Sciences from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Alimera Sciences in a research note on Monday, January 22nd. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $3.31.

In other Alimera Sciences news, CEO C. Daniel Myers sold 52,900 shares of the stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total value of $65,067.00. Following the completion of the sale, the chief executive officer now owns 154,411 shares in the company, valued at approximately $189,925.53. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Philip Ashman sold 25,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $1.23, for a total transaction of $31,365.00. Following the sale, the senior vice president now owns 38,250 shares of the company’s stock, valued at approximately $47,047.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 184,704 shares of company stock valued at $224,432. 14.70% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Insider Buying and Selling by Quarter for Alimera Sciences (NASDAQ:ALIM)

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.

Leave a Reply